BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 59 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q3 2023. The put-call ratio across all filers is 0.29 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $18,057 | -95.4% | 90,242 | -52.5% | 0.00% | -96.8% |
| Q2 2023 | $391,266 | -37.6% | 189,935 | 0.0% | 0.06% | -56.3% |
| Q1 2023 | $626,786 | +101.2% | 189,935 | 0.0% | 0.14% | +89.3% |
| Q4 2022 | $311,494 | -62.9% | 189,935 | 0.0% | 0.08% | -55.1% |
| Q3 2022 | $839,000 | +20.2% | 189,935 | -25.1% | 0.17% | +31.5% |
| Q2 2022 | $698,000 | -31.7% | 253,432 | -16.7% | 0.13% | -5.2% |
| Q1 2022 | $1,022,000 | -11.8% | 304,161 | +5.0% | 0.13% | -22.5% |
| Q4 2021 | $1,159,000 | +21.4% | 289,550 | 0.0% | 0.17% | +158.2% |
| Q3 2021 | $955,000 | -14.3% | 289,550 | -1.2% | 0.07% | -25.6% |
| Q2 2021 | $1,115,000 | -0.6% | 293,200 | 0.0% | 0.09% | +136.8% |
| Q1 2021 | $1,122,000 | -94.3% | 293,200 | -74.9% | 0.04% | -97.3% |
| Q3 2020 | $19,797,000 | – | 1,170,100 | – | 1.43% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SABBY MANAGEMENT, LLC | 242,850 | $923,000 | 0.13% |
| ABNER HERRMAN & BROCK LLC | 241,500 | $918,000 | 0.13% |
| Weaver Consulting Group | 48,881 | $186,000 | 0.10% |
| Tibra Equities Europe Ltd | 87,000 | $331,000 | 0.10% |
| Ikarian Capital, LLC | 293,200 | $1,115,000 | 0.09% |
| GSA CAPITAL PARTNERS LLP | 60,238 | $229,000 | 0.03% |
| Ergoteles LLC | 124,329 | $472,000 | 0.01% |
| CFO4Life Group, LLC | 12,003 | $46,000 | 0.01% |
| HighPoint Advisor Group LLC | 17,033 | $65,000 | 0.01% |
| BOOTHBAY FUND MANAGEMENT, LLC | 32,836 | $125,000 | 0.00% |